Email
Password
Remember meForgot password?
    Log in with Twitter

article imageGenvoya, new HIV-1 new treatment

By Tim Sandle     Dec 4, 2015 in Health
A new treatment for the human immunodeficiency virus (HIV) has been approved for use in the U.S. The treatment comes in pill form.
The treatment has been approved by the U.S. Food and Drug Administration (FDA). It takes the form as a single tablet. The tablet is branded Genvoya, and is made by Gilead Sciences Inc. Genvoya is intended to be a total complete treatment for HIV-1 — the most common and pathogenic strain of the virus — designed to be taken by people aged 12 years and older. Patients must weigh at least 35 kilograms (77 pounds).
Genvoya is composed of the following substances: elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide. The tenofovir constituent was new and had not previously been trialed. Tenofovir is an established antiretroviral medication used to prevent and treat HIV/AIDS and treat chronic hepatitis B.
With the newly formulated tenofovir, the chemical enters HIV-infected cells more efficiently than older versions. Moreover, it can be administered at orally and can be given at a lower dose, which is better for the patient. There have been reported associations between tenofovir levels in the bloodstream and kidney toxicity, as well as reductions in bone density.
The drug is not entirely risk free — it can cause a build-up of lactic acid in the blood and severe liver problems; therefore, a considered view by a medical practitioner is important.
The FDA granted approval following a series of clinical trials. In total some 3,171 subjects were assessed over four trials. The trials involved an assessment of viral loads, and with each subject, there was a noted reduction to a level at least equal to other treatments.
A new drug is welcomed given the continued prevalence of HIV in the U.S. The cumulative number of deaths in the U.S. due to causes related to AIDS is estimated to be more than 650,000, and to date 1.8 million people have become infected with HIV. The U.S. Centers for Disease Control and Infection (CDC) estimates that around 50,000 people are infected each year.
In related HIV drugs news, biotech company Cipla Ltd. has announced it is ready to supply its combinations of Tenofovir/ Emtricitabine / Efavirenz and Tenofovir/ Lamivudine /Efavirenz, with a dose of 400 mg of Efavirenz to act as a first-line initial therapy for HIV infection.
More about HIV, Hiv1, Genvoya, Fda, Gilead Sciences Inc
More news from